Renovaro Inc. (NASDAQ:RENB) Short Interest Update

Renovaro Inc. (NASDAQ:RENB) saw a large growth in short interest in December. As of December 31st, there was short interest totalling 5,060,000 shares, a growth of 30.7% from the December 15th total of 3,870,000 shares. Approximately 6.6% of the shares of the stock are sold short. Based on an average daily volume of 1,030,000 shares, the short-interest ratio is currently 4.9 days.

Renovaro Stock Performance

RENB stock traded down $0.04 during trading on Friday, reaching $0.71. 624,909 shares of the company were exchanged, compared to its average volume of 1,725,119. The stock’s 50 day moving average price is $0.99 and its 200 day moving average price is $0.84. Renovaro has a 52-week low of $0.40 and a 52-week high of $5.25. The company has a market cap of $112.22 million, a P/E ratio of -0.74 and a beta of 0.66.

Institutional Investors Weigh In On Renovaro

Hedge funds and other institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC raised its stake in shares of Renovaro by 193.3% during the 4th quarter. SG Americas Securities LLC now owns 51,725 shares of the company’s stock worth $43,000 after buying an additional 34,090 shares during the last quarter. Rhumbline Advisers purchased a new position in Renovaro during the 2nd quarter valued at about $79,000. State Street Corp raised its position in Renovaro by 3.8% during the third quarter. State Street Corp now owns 1,323,832 shares of the company’s stock worth $640,000 after acquiring an additional 48,114 shares during the last quarter. Barclays PLC lifted its holdings in shares of Renovaro by 315.7% in the third quarter. Barclays PLC now owns 69,531 shares of the company’s stock valued at $34,000 after purchasing an additional 52,804 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of Renovaro by 347.6% in the third quarter. JPMorgan Chase & Co. now owns 93,010 shares of the company’s stock valued at $45,000 after purchasing an additional 72,230 shares during the last quarter. 71.41% of the stock is currently owned by institutional investors and hedge funds.

About Renovaro

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.